ME02189B - Farmaceutski dozni oblici sa kontrolisanim oslobađanjem - Google Patents

Farmaceutski dozni oblici sa kontrolisanim oslobađanjem

Info

Publication number
ME02189B
ME02189B MEP-2015-116A MEP2015116A ME02189B ME 02189 B ME02189 B ME 02189B ME P2015116 A MEP2015116 A ME P2015116A ME 02189 B ME02189 B ME 02189B
Authority
ME
Montenegro
Prior art keywords
pharmaceutical dosage
sustained
matrix formulation
dosage forms
controlled release
Prior art date
Application number
MEP-2015-116A
Other languages
English (en)
Inventor
Haiyong Hugh Huang
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of ME02189B publication Critical patent/ME02189B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (1)

1. Čvrsti oralni farmaceutski dozni oblik sa produženim oslobađanjem koji sadrži višeslojnu formulaciju matrice sa produženim oslobađanjem sa strukturom tipa sendviča ili polu sendviča, a formulacija matrice sa produženim oslobađanjem se sastoji od (1) prve kompozicije koja obrazuje prvi sloj koji sadrži aktivnu materiju formulacije matrice sa produženim oslobađanjem koja sadrži: (a) bar jedan polietilen oksid koji ima na osnovu reoloških merenja, približnu molekulsku masu od bar 1000 000; i (b) bar jednu aktivnu materiju; i (2) druge kompozicije koja obrazuje drugi sloj bez aktivne materije formulacije matrice sa produženim oslobađanjem koja sadrži bar jedan poletilen oksid.
MEP-2015-116A 2011-03-25 2012-03-22 Farmaceutski dozni oblici sa kontrolisanim oslobađanjem ME02189B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161467824P 2011-03-25 2011-03-25
EP20120717468 EP2688556B1 (en) 2011-03-25 2012-03-22 Controlled release pharmaceutical dosage forms
PCT/IB2012/000595 WO2012131463A2 (en) 2011-03-25 2012-03-22 Controlled release pharmaceutical dosage forms

Publications (1)

Publication Number Publication Date
ME02189B true ME02189B (me) 2016-02-20

Family

ID=46018006

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2015-116A ME02189B (me) 2011-03-25 2012-03-22 Farmaceutski dozni oblici sa kontrolisanim oslobađanjem

Country Status (24)

Country Link
US (1) US20140056979A1 (me)
EP (1) EP2688556B1 (me)
JP (1) JP5964940B2 (me)
KR (1) KR101619579B1 (me)
CN (1) CN103547259A (me)
AU (1) AU2012235878B2 (me)
BR (1) BR112013024585A8 (me)
CA (1) CA2831218C (me)
CY (1) CY1116579T1 (me)
DK (1) DK2688556T3 (me)
ES (1) ES2544735T3 (me)
HR (1) HRP20150835T1 (me)
HU (1) HUE026981T2 (me)
IL (1) IL228441B (me)
ME (1) ME02189B (me)
MX (1) MX350875B (me)
PH (1) PH12013501994A1 (me)
PL (1) PL2688556T3 (me)
PT (1) PT2688556E (me)
RS (1) RS54152B1 (me)
SI (1) SI2688556T1 (me)
SM (1) SMT201500209B (me)
WO (1) WO2012131463A2 (me)
ZA (1) ZA201307862B (me)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP2283829A1 (en) 2000-10-30 2011-02-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
WO2010149169A2 (en) 2009-06-24 2010-12-29 Egalet A/S Controlled release formulations
EP2826467B1 (en) 2010-12-22 2017-08-02 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
TWI522101B (zh) 2012-04-17 2016-02-21 普渡製藥有限合夥事業 處理由類鴉片引起之不利的藥效動力反應之系統和方法
US9549899B2 (en) 2012-07-06 2017-01-24 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
CN105120846B (zh) 2013-02-05 2019-10-18 普渡制药公司 抗篡改的药物制剂
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
CA3068036A1 (en) 2017-06-30 2019-01-03 Purdue Pharma L.P. Use to buprenorphine in combination with an opioid to treat pain
EP3675842A4 (en) 2017-08-31 2021-05-19 Purdue Pharma L.P. PHARMACEUTICAL DOSAGE FORMS
KR102810926B1 (ko) 2017-12-20 2025-05-22 퍼듀 퍼머 엘피 남용 억제 황산모르핀 제형

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR950007907B1 (ko) * 1992-09-01 1995-07-21 동국제약 주식회사 치주질환 치료용 막형 국소약물송달제제
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5634702A (en) 1995-09-27 1997-06-03 Fistonich; Juraj Hands free waste container having a closed cover that automatically opens when the container is moved outside its cabinet enclosure
PT1251832E (pt) * 2000-02-04 2007-01-31 Depomed Inc Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero
EP2283829A1 (en) * 2000-10-30 2011-02-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
JP5259183B2 (ja) * 2004-07-01 2013-08-07 グリューネンタール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 乱用に対して保護された経口剤形
US7434308B2 (en) * 2004-09-02 2008-10-14 International Business Machines Corporation Cooling of substrate using interposer channels
CA2605180A1 (en) * 2005-04-19 2006-10-26 Alza Corporation Controlled delivery dosage form of tramadol and gabapentin
WO2007133150A1 (en) * 2006-05-17 2007-11-22 Sandvik Intellectual Property Ab A top hammer rock-drilling tool, a drill rod and coupling sleeve
SA07280459B1 (ar) * 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
WO2009012122A1 (en) * 2007-07-13 2009-01-22 Marvell World Trade Ltd. Method for shallow trench isolation
US8377453B2 (en) * 2008-03-11 2013-02-19 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
CN101933907A (zh) * 2009-06-30 2011-01-05 北京天衡药物研究院 新型骨架缓释片及其制备方法

Also Published As

Publication number Publication date
IL228441A0 (en) 2013-12-31
JP2014510094A (ja) 2014-04-24
WO2012131463A2 (en) 2012-10-04
PH12013501994A1 (en) 2013-12-02
AU2012235878A1 (en) 2013-05-02
CA2831218A1 (en) 2012-10-04
KR101619579B1 (ko) 2016-05-10
RS54152B1 (sr) 2015-12-31
NZ616600A (en) 2015-07-31
SMT201500209B (it) 2015-10-30
CY1116579T1 (el) 2017-03-15
EP2688556B1 (en) 2015-05-06
ES2544735T3 (es) 2015-09-03
JP5964940B2 (ja) 2016-08-03
ZA201307862B (en) 2014-06-25
US20140056979A1 (en) 2014-02-27
AU2012235878B2 (en) 2015-10-15
MX350875B (es) 2017-09-19
MX2013010987A (es) 2014-10-13
SI2688556T1 (sl) 2015-09-30
HUE026981T2 (en) 2016-08-29
WO2012131463A3 (en) 2012-11-29
KR20130135973A (ko) 2013-12-11
CA2831218C (en) 2017-01-17
EP2688556A2 (en) 2014-01-29
BR112013024585A8 (pt) 2018-01-09
HRP20150835T1 (hr) 2015-09-11
CN103547259A (zh) 2014-01-29
PT2688556E (pt) 2015-09-11
DK2688556T3 (en) 2015-08-03
PL2688556T3 (pl) 2015-10-30
IL228441B (en) 2019-05-30

Similar Documents

Publication Publication Date Title
AR081760A1 (es) Una composicion farmaceutica para administracion oral que comprende acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico, un metodo para producir la misma, una tableta y una forma unitaria de dosificacion oral que la comprende y el uso de la misma para la fabricacion de un medicamento
ES2478264T3 (es) Glicerosomas y uso de estos en preparaciones farmacéuticas y cosméticas para aplicación tópica
BRPI0809667A2 (pt) Composto, medicamento e composição farmacêutica que o contém e uso do composto
ECSP14013168A (es) Tableta a prueba de manipulación que proporciona liberación de fármaco inmediato
EA201001244A1 (ru) Система доставки лекарственного средства со стабилизирующим эффектом
JP2010285439A5 (me)
WO2009074351A3 (en) Solid forms of tenofovir disoproxil
CL2011002968A1 (es) Forma de dosificacion de extrusion por fusion caliente de un ingrediente activo (a) incluido en una matriz que comprende un polimero (c), que el nucleo presenta una orientacion morfologica ortogonal respecto a la direccion longitudinal de extension de la forma de dosificacion; y su procedimiento de preparacion.
CY1117735T1 (el) Σκευασμα αντισωματος
CU20080052A7 (es) Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo
EP4209513A4 (en) BISPECIFIC ANTI-VEGF-ANTI-PD-L1 ANTIBODY, PHARMACEUTICAL COMPOSITION THEREOF AND RELATED USES
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
BRPI0814666A2 (pt) composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
BR112012024139A2 (pt) formulações farmacêuticas de camada dupla contendo agonistas e antagonistas de opióide.
ECSP10010224A (es) Formulaciones líquidas de hormona luteinizante (lh).
EA201071204A1 (ru) Применение дронедарона для приготовления лекарственного средства для применения в предотвращении госпитализации в кардиологическое отделение или смертности
JP2015514739A5 (me)
CL2014003237A1 (es) Formulación farmacéutica estable que comprende un anticuerpo anti-dll4 (ligando tipo delta humano 4); y kit que comprende la composición en un envase e instrucciones.
UY32749A (es) Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica
ECSP10010683A (es) Una formulacion farmacéutica sólida
IT1401284B1 (it) Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
WO2011130834A8 (en) Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof
BR112014004753A2 (pt) formulação de liberação de multicamadas
MA50394A (fr) Formulations pharmaceutiques comprenant un agoniste de récepteur d'opioïde en tant que substances actives, leurs procédés de fabrication et leurs utilisations thérapeutiques
CL2008000092A1 (es) Compuestos derivados de 3-cianopiridina, inhibidores del receptor p2y12; composicion farmaceutica que comprende a dichos compustos; y su uso en el tratamiento del transtorno de la agregacion plaquetaria.